'HL/B9E5HL-61NH7*=CGE/Y7~CK
SYSTEM PROCESSING...
'HL/B9E5HL-61NH7*=CGE/Y7~CK
SYSTEM PROCESSING...
Posted: 2025-04-24 05:05:00 UTC
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
Status
Last Updated
2025-04-24 05:05:18 UTC
Verified By
Rollup News
A study reveals that a significant number of patients discontinue oral lipid-lowering drugs after starting PCSK9 inhibitors, highlighting potential implications for cardiovascular disease management.
Discontinuation of oral lipid-lowering drugs after PCSK9 inhibitor initiation
Treatment patterns and adherence to statins and ezetimibe
Analysis of pharmacy dispensing data for PCSK9 mAb users
Determining the reasons for discontinuing oral lipid-lowering drugs
Understanding the impact of discontinuation on cardiovascular outcomes
Ensuring appropriate monitoring and management of patients